Has Inna Shifrin, MD received payments from drug or device companies?

Yes. Drug and device makers reported $21,407 in general payments to Inna Shifrin, MD across 1,131 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Inna Shifrin, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Inna Shifrin, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Inna Shifrin, MD

Geriatric Medicine · Brooklyn, NYNPI 1710967971

Payments from drug & device makers

$21,407in general payments, 2019–2025

Across 1,131 payments — averaging $18.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$3K
AstraZeneca$2K
GSK$2K
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
Lilly USA, LLC$1K
Boehringer Ingelheim$856
plus $11K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	156	$3,030
AstraZeneca	111	$2,248
GSK	91	$1,752
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	112	$1,617
Lilly USA, LLC	71	$1,184
Boehringer Ingelheim	44	$856
Sanofi-aventis U.S. LLC	52	$822
Philips North America LLC	39	$792
Novartis	36	$762
Novo Nordisk	41	$715
Sanofi	24	$670
Merck	40	$663
Aimmune Therapeutics, Inc.	22	$473
Genentech USA, Inc.	17	$345
Abbott	16	$323
Mylan Specialty L.p.	16	$319
Johnson & Johnson	15	$309
Shield Therapeutics Inc	15	$306
Alnylam Pharmaceuticals Inc.	13	$295
Pfizer	14	$247
Axsome Therapeutics, Inc.	13	$243
Avanir Pharmaceuticals, Inc.	11	$229
Amarin Pharma, Inc.	9	$170
Sumitomo Pharma America, Inc.	7	$147
Exact Sciences	6	$131
Ardelyx, Inc.	5	$129
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	6	$127
Regeneron Healthcare Solutions, Inc.	4	$125
IBSA Pharma Inc.	6	$119
Astellas Pharma US Inc	8	$114
Amgen	6	$113
Teva Pharmaceuticals USA, Inc.	7	$112
Kowa Pharmaceuticals America, Inc.	7	$107
Sunovion Pharmaceuticals Inc.	13	$106
E.r. Squibb & Sons, L.L.C.	6	$105
Takeda Pharmaceuticals U.S.A., Inc.	4	$104
Comsort, Inc	1	$100
Esperion Therapeutics, Inc.	5	$99
Lundbeck LLC	4	$98
Phathom Pharmaceuticals, Inc.	4	$92
Bausch Health US, LLC	4	$87
Verona Pharma, Inc.	3	$82
Otsuka America Pharmaceutical, Inc.	3	$73
Paratek Pharmaceuticals, Inc.	4	$73
Nestle Healthcare Nutrition Inc.	4	$71
Corium, LLC	3	$68
Scynexis, Inc.	2	$52
Corcept Therapeutics	2	$51
Vivus LLC	3	$48
Nabriva Therapeutics, PLC	2	$47
Electromed, Inc.	2	$46
Almatica Pharma LLC	2	$44
Intra-sana Laboratories	2	$41
Baxter Healthcare	2	$39
Alfasigma USA, Inc.	2	$37
Scilex Pharmaceuticals Inc.	2	$30
Biohaven Pharmaceuticals, Inc.	1	$28
Currax Pharmaceuticals LLC	2	$26
Insmed, Inc.	1	$24
Eisai Inc.	1	$23

How this compares

$21,407 in reported general payments places this provider in the 95th percentile of 400 geriatric medicine providers in New York.

See all geriatric medicine providers in New York →

Medicare billing

Part B allowed, 2024

$172,108

Medicare patients

256

Services billed

2,608

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other geriatric medicine in Brooklyn

Wen DombrowskiBrooklyn$45K
Sergey GenkinBrooklyn$10K
Diana LevinaBrooklyn$9K
Faina KoganBrooklyn$7K
William PutmanBrooklyn$6K
Roberto RobinsonBrooklyn$6K
Nathalia IdelevitchBrooklyn$5K
Stefano FrancoBrooklyn$3K
Larissa GoldBrooklyn$3K
Howard OrkinBrooklyn$2K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →